CRL · Q4 2025 Earnings
CautiousCharles River Laboratories
Reported January 13, 2026
30-second summary
30-second take: Management introduced FY2026 non-GAAP EPS guidance of $10.70–$11.20 (+4–9% YoY off the $10.28 FY2025 actual) with organic revenue still negative at down 1% to flat, anchored on at least $100M of incremental cost savings, ~$0.25 of KF Cambodia accretion, and >$0.30 of below-the-line benefit (lower tax rate). The composition matters: nearly all the EPS growth is engineered from operational levers and below-the-line items, not top-line acceleration, with DSA recovery deferred to H2 2026 under "cautiously optimistic" language. The hidden negative is RMS, which steps down from FY2025 actual +1.2% organic growth to a low-to-mid single-digit organic decline guide for FY2026 — the cleanest "things got worse" signal on the print. Q4 DSA net book-to-bill came in at 1.12x on $665M of net bookings (vs. 0.82x in Q3), the affirmative answer to last quarter's gating question.
Guidance
FY2026 guidance introduced at $10.70–$11.20 EPS (4–9% growth) with organic revenue expected down 1% to flat, as RMS deteriorates but Manufacturing rebounds and DSA shows cautious optimism for H2 recovery.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Non-GAAP EPS | FY2026 | $10.70 to $11.20 | +4% to +9% |
| Organic Revenue Growth | FY2026 | down 1% to at least flat | — |
| Operating Margin Expansion | FY2026 | 20 to 50 basis points | — |
| RMS Organic Revenue Growth | FY2026 | low to mid single-digit decline | — |
| DSA Organic Revenue Growth | FY2026 | slightly positive to low single-digit decrease | — |
| Manufacturing Organic Revenue Growth | FY2026 | low single-digit increase | — |
| KF Cambodia Acquisition EPS Benefit | FY2026 | approximately $0.25 per share | — |
| Below-the-Line Items Benefit | FY2026 | more than $0.30 at midpoint | — |
| Incremental Cost Savings | FY2026 | at least $100 million above 2025 level | — |
Management tone
Q1 FY2025 defensive uncertainty → Q2 FY2025 "stabilized, gradual progress" → Q3 FY2025 "clear signs of stabilization, industry may be on path to recovery" → Q4 FY2025 "cautiously optimistic, return to growth in H2 2026."
The headline tonal shift across four quarters is from passive observation of stabilization to active commitment to a recovery trajectory — but management deliberately stopped short of guiding to consolidated organic growth in FY2026. The anchor quote: "we are cautiously optimistic that the favorable DSA demand trends will continue in 2026 and result in a return to organic revenue growth in the second half of the year for both the DSA segment and the overall company." Three quarters ago this language did not exist; last quarter management explicitly refused to commit to 2026; this quarter the commitment is qualified but present. The signal is real, but the hedging ("cautiously," "we believe," "subject to") is heavier than the prepared-remarks framing implies.
NAMs framing inverted across three quarters from existential risk to non-event. Last spring NAMs was treated as a potential structural disruption to safety assessment demand; this quarter management stated "there have not been any significant technological changes in drug development, and we have not experienced any notable changes in client behavior other than more frequent conversations about NAMs." The shift signals management now considers the NAMs disruption thesis empirically falsified to date — a meaningful narrative win for the bull case, though management was careful to frame it as a gradual longer-term evolution rather than a closed chapter.
The NHP narrative completed a three-quarter arc from structural vulnerability to M&A-driven margin tailwind. Q2 FY2025 resolved the Cambodia investigation overhang; Q3 FY2025 flagged third-party NHP sourcing as a Q4 cost drag; this quarter management framed KF Cambodia as the structural fix: "we expect NHP sourcing costs will normalize over the course of the year… meaningful margin improvement starting later this year through significant cost savings on NHP sourcing." The transformation of NHP from defensive headache to ~$0.25 EPS accretion in FY2026 (and ~$0.60 in FY2027 per management) is the cleanest example of execution against a prior-quarter risk.
The Manufacturing tone reversed sharply. Q3 FY2025 quietly trimmed Manufacturing to "flat to slightly lower"; FY2025 closed at -1.6% organic and Q4 at -2.1%, yet the segment is guided to a low single-digit increase in FY2026. The bridge per management: anniversarying the ~$20M H1 2025 commercial cell therapy client loss in CDMO, continued mid-single-digit growth in microbial solutions, and recovery in biologics testing as client-specific delays anniversary. Worth pressure-testing next quarter.
Most importantly, the FY2026 EPS construction reveals a shift in posture from "protect margin while waiting for revenue" to "engineer EPS growth from non-operating levers while waiting for revenue." The anchor quote: "We expect to generate at least $100 million in incremental cost savings above the 2025 level to help protect the operating margin because revenue growth will not offset the level of annual cost inflation this year." The admission that revenue growth doesn't cover inflation — even after returning to organic flat — is the most candid line on the call and reframes how investors should read the +4–9% EPS guide.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Eric Holdwell · Baird
Clarification on NHP dynamics: RMS facing lower volumes while DSA facing higher sourcing costs despite strong demand. Request for explanation of the divergence and drivers of sourcing cost increases.
RMS volume decline is primarily timing-related with shipments shifting; DSA sourcing costs increased because more NHP studies came in than expected, requiring open market purchases at higher prices. The mismatch stems from two separate sourcing locations (Asia and Mauritius) not aligning perfectly with internal farm availability.
Luke Circuit · Barclays
DSA capacity and hiring needs as demand ramps. With bookings improving but management having already hired ahead of expected demand, discussion of physical capacity utilization and headcount planning relative to margin outlook.
Physical capacity is in good shape and not optimally utilized; management is being measured on hiring direct labor, bringing people on a quarter before needed due to training requirements. Confident in ability to accommodate work without dragging operating margins.
Dave Windley · Jefferies
Temperature check on client demand urgency and booking trends into early 2026, comparing to prior year and Q4 momentum. Follows up on conservative book-to-bill requirement for guidance achievement.
Demand improving from biotech funding inflows and pharma portfolio restructuring. Seeing shift toward earlier-stage general talks (pre-IND) rather than post-IND work, indicating more balanced demand profile and client urgency. Book-to-bill >1 in Q4 strong but conversion lags by 1-2 quarters; need sustained >1 book-to-bill but acknowledge timing variability.
Charles Rhee · TD Cowen
Guidance outlook and margin improvement drivers: which headwinds fully exit Q1 versus carry through, and whether margin improvement follows a step function into Q2 or gradual ramp.
Three main drivers of sequential margin improvement: (1) continued cost savings benefits throughout year, (2) NHP sourcing costs decline as KF supply ramps (Q1 headwind from bolus of demand dissipates), and (3) demand growth materializing into revenue. Also noted Q1 stock comp headwind from executive transition accelerates expense. Not a full step function but gradual improvement.
Michael Riskin · Bank of America
On demand volatility: 2025 had strong start then summer lull then late-year pickup. What gives confidence that Q4 strength is not a 'red herring' and similar patterns won't repeat in 2026? Attribution of 2025 volatility to macro versus other factors.
2025 slowdown attributed to biotech funding constraints and large pharma cost-cutting. Confidence in 2026 stems from: (1) $28B biotech funding in Q4, (2) continuation into January, (3) typical 1-2 quarter lag before funded biotech companies deploy capital into studies, (4) book-to-bill >1 positioning for H2 benefit. Being cautiously optimistic but acknowledging non-linearity.
Answers to last quarter's watch list
What to watch into next quarter
DSA book-to-bill sustaining above 1.0x for two consecutive quarters: Q4 cleared 1.12x and January was "a good month," but management's own framing requires sustained >1.0x bookings averaging above one for the year to hit the top end of the DSA range. A Q1 print back below 1.0x would force the H2 recovery thesis into question.
Divestiture transaction announcement by Q1 FY2026 release: the Q3 FY2025 commitment to ~7% of revenue divesting has not converted into a transaction, and accretion has already been re-cut from $0.30 annualized to ~$0.10 partial-year for FY2026. Continued absence of a definitive announcement would suggest the strategic review's quantified outputs are slipping further.
RMS organic revenue trajectory vs. low-to-mid single-digit decline guide: this is the segment that deteriorated this quarter, stepping from +1.2% FY2025 actual to a low-to-mid single-digit decline guide. A Q1 print better than -4% organic suggests timing genuinely drove the weakness; worse than -5% suggests structural early-stage biotech demand is deteriorating.
Q1 FY2026 non-GAAP operating margin print: management guided to mid-teens with NHP sourcing costs, staffing ramp, and CEO transition stock comp (~$0.15 EPS) as Q1-specific headwinds expected to dissipate. A Q1 margin meaningfully below mid-teens would suggest the headwinds are larger than telegraphed; a sequential snap-back in Q2 validates the "discrete and temporary" framing.
EPS bridge composition vs. guide: management built FY2026 EPS growth on ~$0.25 KF accretion and >$0.30 below-the-line. Watch whether KF accretion tracks on schedule (likely H2-weighted) and whether the 22–23% tax rate assumption holds through the year — if either slips, the +4–9% EPS guide compresses quickly.
Sources
- Charles River Laboratories Form 8-K cover filing, filed 2026-01-13. https://www.sec.gov/Archives/edgar/data/1100682/000162828026001905/R1.htm
- Charles River Laboratories Q4 FY2025 earnings conference call (prepared remarks and Q&A).
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.